luspatercept

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

B-Thalassemia

Conditions

B-Thalassemia

Trial Timeline

Feb 28, 2013 → Nov 11, 2015

NCT ID

NCT01749540

About luspatercept

luspatercept is a phase 2 stage product being developed by Merck for B-Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01749540. Target conditions include B-Thalassemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03342404	Phase 2	Completed	Feb 5, 2018	Nov 28, 2022	Thalassemia
NCT02604433	Phase 3	Completed	May 2, 2016	Jan 5, 2021	Erythrocyte Transfusion
NCT02631070	Phase 3	Completed	Feb 9, 2016	Nov 26, 2020	Myelodysplastic Syndromes
NCT02268409	Phase 2	Completed	Oct 20, 2014	Jun 18, 2020	β-Thalassemia
NCT02268383	Phase 2	Completed	Oct 9, 2014	Mar 19, 2020	Myelodysplastic Syndromes
NCT01749540	Phase 2	Completed	Feb 28, 2013	Nov 11, 2015	B-Thalassemia
NCT01749514	Phase 2	Completed	Jan 21, 2013	Oct 22, 2018	Anemia

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved